Open access
Open access
Powered by Google Translator Translator

Critical Care & Emergencies (all articles)

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

17 Dec, 2021 | 09:52h | UTC

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)

 

NICE Guideline | Acute heart failure: diagnosis and management.

17 Dec, 2021 | 08:48h | UTC

Acute heart failure: diagnosis and management – National Institute for Health and Care Excellence

Related: #ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

 

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021.

17 Dec, 2021 | 08:36h | UTC

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Commentary on Twitter

 

Autoimmune encephalitis after SARS-CoV-2 infection: case frequency, findings, and outcomes.

16 Dec, 2021 | 09:47h | UTC

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

 

Commentary on Twitter

 

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

16 Dec, 2021 | 09:52h | UTC

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Related:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Recommendations for antibiotic selection for severe nosocomial infections.

16 Dec, 2021 | 09:40h | UTC

Recommendations for antibiotic selection for severe nosocomial infections – Revista Espanola de Quimioterapia

 

Review: Impact of obesity in critical illness.

16 Dec, 2021 | 08:45h | UTC

Impact of Obesity in Critical Illness – CHEST

 

A guide to enteral nutrition in intensive care units: 10 expert tips for the daily practice.

16 Dec, 2021 | 08:47h | UTC

A guide to enteral nutrition in intensive care units: 10 expert tips for the daily practice – Critical Care

 

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

15 Dec, 2021 | 08:46h | UTC

News release: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Commentaries:

Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT

Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press

Related:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

 

Commentary on Twitter (thread – click for more)

 

Position Paper: Diagnosis, management, and prevention of button battery ingestion in childhood.

15 Dec, 2021 | 08:32h | UTC

Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood: A European Society for Paediatric Gastroenterology Hepatology and Nutrition Position Paper – Journal of Pediatric Gastroenterology and Nutrition

Visual summary: Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood

 

Commentary on Twitter (thread – click for more)

 

Review: Diagnosis and management of acute appendicitis in adults.

15 Dec, 2021 | 08:28h | UTC

Diagnosis and Management of Acute Appendicitis in Adults: A Review – JAMA (free for a limited period)

Author Interview: Current Management of Acute Appendicitis: Antibiotics or Surgical Intervention

Commentary: Antibiotics can be first-line therapy for uncomplicated appendicitis cases – Duke University Medical Center

 

Infectious diseases learning pearls from inpatient ID consults.

15 Dec, 2021 | 08:22h | UTC

ID Learning Units from Inpatient ID Consults – HIV and ID Observations

 

Podcast: No tension about inpatient hypertension.

14 Dec, 2021 | 08:39h | UTC

#310 No Tension About Inpatient Hypertension with Dr. Noble Maleque – The Curbsiders

 

How to recognize and manage COVID-19-associated coagulopathy.

13 Dec, 2021 | 09:45h | UTC

How to recognize and manage COVID-19-associated coagulopathy – Hematology, ASH Education Program

 

COVID-19 and thrombosis: searching for evidence.

13 Dec, 2021 | 09:47h | UTC

COVID-19 and thrombosis: searching for evidence – Hematology, ASH Education Program

 

M-A: Performance of the European Society of Cardiology 0/1-hour, 0/2-hour, and 0/3-hour algorithms for rapid triage of acute myocardial infarction.

10 Dec, 2021 | 10:09h | UTC

Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction: An International Collaborative Meta-analysis – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentaries:

Rapid ESC hs-cTn Algorithms Best 3-Hour Protocol for MI Rule-out: Meta-analysis – TCTMD

Performance of ESC 0/1-, 0/2-, 0/3-Hour Algorithms for AMI Compared – HealthDay

 

Commentary on Twitter

 

M-A: Intravenous diltiazem vs. metoprolol for atrial fibrillation with rapid ventricular rate.

10 Dec, 2021 | 10:05h | UTC

Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis – The American Journal of Emergency Medicine (link to abstract – $ for full-text)

 

Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis.

10 Dec, 2021 | 09:58h | UTC

Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis – United European Gastroenterology Journal

 

Review: Neuropsychiatric assessment and management of the ICU survivor.

10 Dec, 2021 | 10:01h | UTC

Neuropsychiatric assessment and management of the ICU survivor – Cleveland Clinic Journal of Medicine

 

RCT: In critically ill adults undergoing tracheal intubation, use of a bougie did not significantly increase the incidence of successful first attempt intubation vs. with use of an endotracheal tube with stylet.

9 Dec, 2021 | 10:22h | UTC

Effect of Use of a Bougie vs Endotracheal Tube With Stylet on Successful Intubation on the First Attempt Among Critically Ill Patients Undergoing Tracheal Intubation: A Randomized Clinical Trial – JAMA (free for a limited period)

Related: Randomized Trial: Comparison of Intubation Techniques in Patients with Difficult Airways

 

M-A: Effects of immediate or early oral feeding on acute pancreatitis.

9 Dec, 2021 | 10:14h | UTC

Effects of immediate or early oral feeding on acute pancreatitis: A systematic review and meta-analysis – Pancreatology

 

Review: Current issues in the use of opioids for the management of postoperative pain.

9 Dec, 2021 | 10:18h | UTC

Current Issues in the Use of Opioids for the Management of Postoperative Pain: A Review – JAMA Surgery (free for a limited period)

 

Update in the diagnosis and management of acute pulmonary embolism for the non-respiratory physician.

9 Dec, 2021 | 10:00h | UTC

Update in the diagnosis and management of acute pulmonary embolism for the non-respiratory physician – Clinical Medicine Journal

 

Blood sugar targets in surgical intensive care: management and special considerations in patients with diabetes.

9 Dec, 2021 | 10:06h | UTC

Blood Sugar Targets in Surgical Intensive Care – Deutsches Ärzteblatt International

 

WHO recommends against the use of convalescent plasma to treat COVID-19.

8 Dec, 2021 | 10:24h | UTC

News Release: WHO recommends against the use of convalescent plasma to treat COVID-19 – World Health Organization

See Guidance: WHO’s living guidelines on COVID-19 therapeutics

Infographic: A living WHO guideline on drugs for covid-19 – The BMJ

 

Commentary on Twitter (thread – click for more)

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.